News

In addition, following positive Phase 1/2 study results, a Phase 3 study evaluating rilzabrutinib for ITP has been initiated. Rilzabrutinib received orphan drug designation from the FDA for

The data analysis showed a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection (primary infection), as well as in participants with and without prior SARS-CoV-2

The trial is enrolling adult epilepsy patients with temporal lobe onset, with or without secondary generalized seizures. A clinical feasibility study at St. Vincent’s Hospital Melbourne (published in The

With the closing of the deal, MyoKardia now operates as a wholly-owned subsidiary of BMS. The deal provides BMS with MyoKardia’s mavacamten, which is a potential first-in-class cardiovascular

This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines. “We appreciate the collaboration with the UK Government as with

The status was based on efficacy and safety results from HPTN 083 phase IIb/III randomised, multicentre, double-blind and clinical trial. The study compared long-acting and injectable cabotegravir to

The study, IMPOWER 22, will evaluate the efficacy and safety of islatravir — Merck’s novel investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) under evaluation for both treatment and

“There is a critical unmet need for people living with Wolfram syndrome, a rare genetic disease in which many patients die prematurely with severe neurological disabilities,” said Wolfram

The independent and NIH-appointed Data Safety Monitoring Board (DSMB) revealed that the mRNA-1273 candidate has demonstrated an efficacy rate of 94.5% in the first interim analysis of the